These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25309634)

  • 1. Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects.
    Gabelli SB; Echeverria I; Alexander M; Duong-Ly KC; Chaves-Moreira D; Brower ET; Vogelstein B; Amzel LM
    Biophys Rev; 2014 Mar; 6(1):89-95. PubMed ID: 25309634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric Activation of PI3Kα Results in Dynamic Access to Catalytically Competent Conformations.
    Chakrabarti M; Gabelli SB; Amzel LM
    Structure; 2020 Apr; 28(4):465-474.e5. PubMed ID: 32049032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of Class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants.
    Wu H; Shekar SC; Flinn RJ; El-Sibai M; Jaiswal BS; Sen KI; Janakiraman V; Seshagiri S; Gerfen GJ; Girvin ME; Backer JM
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20258-63. PubMed ID: 19915146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mechanism of PI3Kα activation at the atomic level.
    Zhang M; Jang H; Nussinov R
    Chem Sci; 2019 Mar; 10(12):3671-3680. PubMed ID: 30996962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structural basis for Ras activation of PI3Kα lipid kinase.
    Zhang M; Jang H; Nussinov R
    Phys Chem Chem Phys; 2019 Jun; 21(22):12021-12028. PubMed ID: 31135801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering of an isolated p110α subunit of PI3Kα permits crystallization and provides a platform for structure-based drug design.
    Chen P; Deng YL; Bergqvist S; Falk MD; Liu W; Timofeevski S; Brooun A
    Protein Sci; 2014 Oct; 23(10):1332-40. PubMed ID: 25043846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
    Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
    Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
    Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
    J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of the p85/p110alpha phosphatidylinositol 3'-kinase. Distinct roles for the n-terminal and c-terminal SH2 domains.
    Yu J; Wjasow C; Backer JM
    J Biol Chem; 1998 Nov; 273(46):30199-203. PubMed ID: 9804776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells.
    Layton MJ; Rynkiewicz NK; Ivetac I; Horan KA; Mitchell CA; Phillips WA
    Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha.
    Huang CH; Mandelker D; Gabelli SB; Amzel LM
    Cell Cycle; 2008 May; 7(9):1151-6. PubMed ID: 18418043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
    Hon WC; Berndt A; Williams RL
    Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B.
    Li X; Dai J; Ni D; He X; Zhang H; Zhang J; Fu Q; Liu Y; Lu S
    Int J Biol Macromol; 2020 Feb; 144():643-655. PubMed ID: 31816384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA).
    Burke JE; Perisic O; Masson GR; Vadas O; Williams RL
    Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic mutations of PIK3CA lead to increased membrane recruitment driven by reorientation of the ABD, p85 and C-terminus.
    Jenkins ML; Ranga-Prasad H; Parson MAH; Harris NJ; Rathinaswamy MK; Burke JE
    Nat Commun; 2023 Jan; 14(1):181. PubMed ID: 36635288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capitalizing on tumor genotyping: towards the design of mutation specific inhibitors of phosphoinsitide-3-kinase.
    Gabelli SB; Duong-Ly KC; Brower ET; Amzel LM
    Adv Enzyme Regul; 2011; 51(1):273-9. PubMed ID: 21035489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural effects of oncogenic PI3Kα mutations.
    Gabelli SB; Huang CH; Mandelker D; Schmidt-Kittler O; Vogelstein B; Amzel LM
    Curr Top Microbiol Immunol; 2010; 347():43-53. PubMed ID: 20593314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of constitutive phosphoinositide 3-kinase activation by oncogenic mutants of the p85 regulatory subunit.
    Shekar SC; Wu H; Fu Z; Yip SC; Nagajyothi ; Cahill SM; Girvin ME; Backer JM
    J Biol Chem; 2005 Jul; 280(30):27850-5. PubMed ID: 15932879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.